Trial Profile
Relative Bioavailability of Dabigatran and Digoxin After 150 mg BID Dabigatran Etexilate and Digoxin at 0.25 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Three-way Crossover Study)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Digoxin
- Indications Embolism and thrombosis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 05 Nov 2010 New trial record.